Reply to : Xing H, Su YZ. JAK inhibitors did not increase the risk of major adverse cardiovascular events in patients with rheumatoid arthritis within the first two years of treatment: comment on the article by Aymon et al. Arthritis Rheumatol. 2025 Sep 1. doi: 10.1002/art.43369. Epub ahead of print. PMID: 40888105.

Regarding : Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D, Codreanu C, Di Giuseppe D, Flouri I, Huschek D, Hyrich KL, Iannone F, Kvien TK, Leeb BF, Nordström D, Otero-Varela L, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Sidiropoulos P, Provan SA, Strangfeld A, Nina T, Zavada J, Kearsley-Fleet L, Courvoisier DS, Finckh A, Lauper K. Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries. Arthritis Rheumatol. 2025 Sep;77(9):1194-1204. doi: 10.1002/art.43188. Epub 2025 May 21. PMID: 40230232; PMCID: PMC12401813. unige:185210